Filing Overview
MIRA Pharmaceuticals, Inc. filed a Form 8-K on May 29, 2024, reporting an event dated May 28, 2024, under Item 5.02. The filing concerns an amendment to Chief Executive Officer Erez Aminov’s employment agreement. MIRA is an emerging growth company, and its common stock trades on Nasdaq under the symbol MIRA.
Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, liquidity, or other operating financial metrics.
Material Changes
- Effective June 1, 2024, Mr. Aminov’s annual base salary increases to $0.3 million.
- If terminated without cause or he resigns for good reason outside a change of control, he will generally receive one year of base salary, with 75% payable in a lump sum after the release-effective date and 25% paid as salary continuation over six months.
- In that circumstance, stock options that would have vested during the following 12 months will vest immediately and remain exercisable for three months after termination.
- If terminated without cause or he resigns for good reason within 18 months after a change of control, he will generally receive 1.5 times the sum of base salary and target annual bonus in a lump sum, plus the same 12-month accelerated option vesting.
Outlook, Risks, and Unusual Items
The Compensation Committee approved the amendment after reviewing information from a third-party compensation consultant. The amendment creates increased potential compensation and equity-vesting obligations upon specified termination events, particularly following a change of control. The filing provides no business outlook or financial guidance.
The full Second Amendment is not included in this filing and is expected to be filed as an exhibit to MIRA’s Form 10-Q for the quarter ending June 30, 2024.
Investor Verification Items
- Verify the complete Second Amendment when it is filed with the Form 10-Q.
- Assess the potential cash and equity dilution implications of the severance and accelerated-vesting provisions.
- Confirm Mr. Aminov’s target annual bonus and the defined terms governing termination, good reason, and change of control.
- Review subsequent filings for any compensation, employment, or change-of-control developments.